AI-drug discovery

BioSymetrics, a phenomics-driven AI drug discovery company, announced that John Baldoni will join its strategic advisory board. John is a…

Elix, and SEEDSUPPLY Inc. hereby announce the start of joint research. Latest Aithority Insights : Adobe Target Announces New AI-enriched…

Syntekabio’s AI platform DeepMatcher will verify and expand the application of MD102 developed by MDBioLab Syntekabio , an AI drug discovery and…

Standigm Inc., the leading workflow artificial intelligence (AI) drug discovery company, announced the appointment of Chief Business Officer Carl…

Global AI drug discovery and development company Syntekabio will present its innovative and efficient proprietary AI-based drug discovery cloud…

Agreement includes upfront payment of $20 million with the potential for $1 billion in milestone-based payments plus tiered royalties Atomwise, a…

Elix, Inc., an AI drug discovery company with the mission of “Rethinking Drug Discovery” (CEO: Shinya Yuki/Headquarters: Tokyo; hereafter referred to…

Standigm Inc., the leading workflow artificial intelligence (AI) drug discovery company, announced the signing of a Memorandum of Understanding (MOU)…

Genesis Therapeutics, a company pioneering artificial intelligence technologies to create medicines for patients with severe and unmet medical…

Arctoris and Evariste Technologies announce a joint venture to develop novel small molecule kinase inhibitors for non-small cell lung cancer (NSCLC).…